UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 23, 2006
IMMTECH PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware 8733 39-1523370
(State or Other (Commission File Number) (I.R.S. Employer
Jurisdiction of Identification No.)
Incorporation)
150 Fairway Drive, Suite 150, Vernon Hills, Illinois 60061
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (847) 573-0033
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
Immtech Pharmaceuticals, Inc. received a commitment for expanded
funding from the University of North Carolina at Chapel Hill ("UNC") under the
Clinical Research Subcontract as amended and restated, effective as of March 28,
2006. The funding commitment to Immtech is based on an expanded commitment of
about $22.6 million funded by the Bill and Melinda Gates Foundation in a grant
to UNC to develop a treatment for human African sleeping sickness ("HAT").
Pursuant to the commitment from UNC, Immtech will receive a total of $13.6
million over the next five years to accelerate development of its lead drug,
pafuramidine maleate (DB289), for the treatment of HAT. Immtech received the
first installment of $5.6 million this week. The majority of this additional
funding will be used by Immtech to accelerate ongoing Phase III clinical testing
of pafuramidine for HAT treatment, to further manufacturing of the lead drug,
and to complete regulatory submissions in preparation for commercialization. The
additional grant increases the funding commitment from the Foundation to UNC to
approximately $40 million and from UNC to Immtech to approximately $25.3
million.
The information in this Item 7.01 and in the accompanying Exhibit
99.1 shall not be deemed to be "filed" for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
The following exhibit is furnished as part of this Report:
--------------------------------------------------------------------------------
Exhibit Number Description
--------------------------------------------------------------------------------
99.1 Press release dated May 23, 2006 announcing the grant of
expanded funding to the Company under a Clinical Research
Subcontract from the University of North Carolina at Chapel
Hill.
--------------------------------------------------------------------------------
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
IMMTECH PHARMACEUTICALS, INC.
Date: May 25, 2006 By: /s/ Eric L. Sorkin
----------------------------
Eric L. Sorkin
Chief Executive Officer and
President